Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cumberland Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01334944
First received: April 12, 2011
Last updated: May 20, 2014
Last verified: May 2014
Results First Received: April 15, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Pain
Fever
Intervention: Drug: Intravenous ibuprofen

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Adult patients in the hospital setting experiencing pain and/or fever.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Patients who met all the inclusion and none of the exclusion criteria during the Screening /Baseline Period were enrolled into the study.

Subjects could not have a history of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin (or aspirin related products) or NSAIDS.


Reporting Groups
  Description
Fever Intravenous ibuprofen (400 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period. Patients may receive up to five additional doses of 400 mg (every four hours), as determined by the investigator
Pain Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period. Patients may receive up to three additional doses of 800 mg (every six hours), as determined by the investigator

Participant Flow:   Overall Study
    Fever     Pain  
STARTED     11 [1]   139 [1]
COMPLETED     11 [1]   139 [1]
NOT COMPLETED     0     0  
[1] Enrollment 150: 97 Participants received a single dose and 53 participants received multiple doses



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Intravenous Ibuprofen

Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.

Intravenous ibuprofen: 400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes


Baseline Measures
    Intravenous Ibuprofen  
Number of Participants  
[units: participants]
  150  
Age, Customized [1]
[units: years]
 
Greater than or equal to 18 years of age     150  
Gender  
[units: participants]
 
Female     91  
Male     59  
Race (NIH/OMB)  
[units: participants]
 
American Indian or Alaska Native     0  
Asian     3  
Native Hawaiian or Other Pacific Islander     1  
Black or African American     34  
White     106  
More than one race     0  
Unknown or Not Reported     6  
Region of Enrollment  
[units: participants]
 
United States     150  
[1] Greater than or equal to 18 years of age



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.   [ Time Frame: 6 hours ]

2.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.   [ Time Frame: 6 hours ]

3.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting   [ Time Frame: 1 hour ]

4.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.   [ Time Frame: 1 hour ]

5.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.   [ Time Frame: 1 hour ]

6.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.   [ Time Frame: 1 hour ]

7.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.   [ Time Frame: 1 hour ]

8.  Secondary:   To Determine the Efficacy of a Single Dose of 400 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever   [ Time Frame: 4 hours ]

9.  Secondary:   To Determine the Efficacy of a Single Dose of 800 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Pain (Mild to Moderate or Moderate to Severe).   [ Time Frame: 4 hours ]

10.  Secondary:   To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain   [ Time Frame: 24 hours ]

11.  Secondary:   To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain   [ Time Frame: 24 hours ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Amy Rock
Organization: Cumberland Pharmaceutical Inc.
phone: 615-255-0068
e-mail: arock@cumberlandpharma.com


No publications provided


Responsible Party: Cumberland Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01334944     History of Changes
Other Study ID Numbers: CPI-CL-015
Study First Received: April 12, 2011
Results First Received: April 15, 2014
Last Updated: May 20, 2014
Health Authority: United States: Food and Drug Administration